Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gennigens

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
ESMO Open|September 15, 2022
Recurrent or primary metastatic cervical cancer: current and future treatmentsC Gennigens, G Jerusalem, L Lapaille, et al.
Revue Medicale De Liege|August 1, 2009
[Monoclonal antibodies and breast cancer. Current therapeutic progress]J Collignon, C Gennigens, A Rorive, et al.
Revue Medicale De Liege|April 24, 2010
["Triple negative" breast cancer]P Freres, J Collignon, C Gennigens, et al.
Revue Medicale De Liege|May 15, 2014
[Multidisciplinary treatment of glioblastoma]N Barthelemy, C Gennigens, F Scholtes, et al.
Facts, Views & Vision in Obgyn|October 30, 2020
Treatment algorithm in patients with ovarian cancerI Vergote, H Denys, J De Greve, et al.
Facts, Views & Vision in Obgyn|July 5, 2022
Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinionI Vergote, H Denys, S Altintas, et al.
Revue Medicale De Liege|June 3, 2021
[Locally-advanced cervix cancer : multidisciplinary management]L Lapaille, M De Cuypere, F Goffin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2022
Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in EuropeA Lamarca, M Morfouace, S Tejpar, et al.
Gynecologic Oncology|May 11, 2023
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancerI Vergote, E Van Nieuwenhuysen, A Casado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2024
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trialM A Powell, L Bjørge, L Willmott, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
ESMO Open|September 15, 2022
Recurrent or primary metastatic cervical cancer: current and future treatmentsC Gennigens, G Jerusalem, L Lapaille, et al.
Revue Medicale De Liege|August 1, 2009
[Monoclonal antibodies and breast cancer. Current therapeutic progress]J Collignon, C Gennigens, A Rorive, et al.
Revue Medicale De Liege|April 24, 2010
["Triple negative" breast cancer]P Freres, J Collignon, C Gennigens, et al.
Revue Medicale De Liege|May 15, 2014
[Multidisciplinary treatment of glioblastoma]N Barthelemy, C Gennigens, F Scholtes, et al.
Facts, Views & Vision in Obgyn|October 30, 2020
Treatment algorithm in patients with ovarian cancerI Vergote, H Denys, J De Greve, et al.
Facts, Views & Vision in Obgyn|July 5, 2022
Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinionI Vergote, H Denys, S Altintas, et al.
Revue Medicale De Liege|June 3, 2021
[Locally-advanced cervix cancer : multidisciplinary management]L Lapaille, M De Cuypere, F Goffin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2022
Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in EuropeA Lamarca, M Morfouace, S Tejpar, et al.
Gynecologic Oncology|May 11, 2023
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancerI Vergote, E Van Nieuwenhuysen, A Casado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2024
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trialM A Powell, L Bjørge, L Willmott, et al.
Pageof 3